Pulmonary surfactant (PS) has been extensively studied because of its primary role in mammalian breathing. The deposition of this surface-active material at the alveolar air-water interface is essential to lower surface tension, thus avoiding alveolar collapse during expiration. In addition, PS is involved in host defense, facilitating the clearance of potentially harmful particulates. PS has a unique composition, including 92% of lipids and 8% of surfactant proteins (SPs) by mass. Although they constitute the minor fraction, SPs to a large extent orchestrate PS-related functions. PS contains four surfactant proteins (SPs) that can be structurally and functionally divided in two groups, i.e. the large hydrophilic SP-A and SP-D and the smaller hydrophobic SP-B and SP-C. The former belong to the family of collectins and are involved in opsonization processes, thus promoting uptake of pathogens and (nano)particles by phagocytic cell types. The latter SPs regulate interfacial surfactant adsorption dynamics, facilitating (phospho)lipid transfer and membrane fusion processes. In the context of pulmonary drug delivery, the exploitation of PS as a carrier to promote drug spreading along the alveolar interface is gaining interest. In addition, recent studies investigated the interaction of PS with drug-loaded nanoparticles (nanomedicines) following pulmonary administration, which strongly influences their biological fate, drug delivery efficiency and toxicological profile. Interestingly, the specific biophysical mode-of-action of the four SPs affect the drug delivery process of nanomedicines both on the extra-and intracellular level, modulating pulmonary distribution, cell targeting and intracellular delivery. This knowledge can be harnessed to exploit SPs for the design of unique and bio-inspired drug delivery strategies.
Introduction
Pulmonary surfactant (PS) is a complex mixture of proteins and lipids that lines the entire alveolar respiratory epithelium and is essential for mammalian breathing. PS is synthetized by alveolar type II pneumocytes and secreted via specialized organelles, i.e. lamellar bodies, in the alveolar lumen. Once secreted, it forms a stable surface-active film onto the air-water interface, lowering the surface tension at this interface to prevent alveolar collapse during expiration.
Human lung surfactant is mainly composed of lipids (92%), with the fully saturated dipalmitoylphosphatidylcholine (DPPC) as the major phospholipid. Besides DPPC, PS also comprises unsaturated phosphatidylcholine (PC), anionic phosphatidylglycerol (PG) and phosphatidylinositol (PI) as well as neutral lipids of which cholesterol is most prominent (Chol). The coexistence of unsaturated and saturated treatment to date is lung transplantation [4] . SP-C deficiency, although not lethal, causes chronic lung disease for which a combination of steroids, hydroxychloroquine, and azithromycin represents the first line treatment [5] . The presence of these four proteins, which will be more elaborately described in Sections 2 and 3, strongly determines both the immunoregulatory and mechanical function of the pulmonary surfactant to protect the human body from invading pathogens or other potentially harmful particulates and to support breathing, respectively.
Next to its vital endogenous function, PS is also clinically applied as a drug product in surfactant replacement therapy (SRT). Lack of fully differentiated alveolar type II cells in premature babies [6] results in defective PS synthesis and secretion, leading to the so-called infant respiratory distress syndrome (IRDS). Several pioneering studies on the biophysical properties of PS and the pathological consequences of its deficiency in premature babies suggested the potential therapeutic benefit of a PS replacement therapy in IRDS. In 1953, Ravenel was the first to propose the use of a Triton WR-1339-based detergent "Alevaire" to treat neonatal asphyxia, an approach that frequently resulted in neonatal death. Further work revealed the key importance of the hydrophobic surfactant proteins SP-B and SP-C, in combination with PSrelated lipids, to develop an effective replacement therapy in RDS [7] . In 1983, Curstedt and Robertson evaluated the therapeutic efficacy of the intratracheal instillation of the natural lung surfactant extracted from porcine minced lungs, containing 99% phospholipids (including around 40% DPPC) and 1% hydrophobic surfactant proteins (SP-B and SP-C) on preterm babies with IRDS [8] . Curosurf®, a name derived from the surnames of its inventors, represented a breakthrough in the SRT and encouraged further studies on the optimization of its composition, drawing a more detailed and complex picture of the biophysical properties of this endogenous surface active material. Other studies also led to the development of alternative animal-derived surfactants as Survanta® or Infasurf®, both from bovine origin [9] . To overcome the drawbacks of animal-derived surfactant preparations and recognizing the importance of SP-B and SP-C for the surface spreading properties of PS, synthetic SRT formulations were developed with SP-B/SP-C analogues that mimic their structure and biophysical properties. Surfaxin® is a formulation consisting of DPPC, PG, palmitic acid (PA) and KL4 (or Sinapultide), the latter being a peptide that mimics certain sequence motifs from the C-terminal domain of SP-B. Surfaxin® was the first synthetic SRT approved by the FDA in 2012 as preventive therapy in premature babies with RDS [10] . Walther et al. investigated the surface activity of in-house developed Mini-B and Super Mini-B (peptides including both N-and C-terminal sequences of the native protein) in vitro and in vivo suggesting these "shortcut versions" as potential candidates in replacement therapies [11] . Finally, the most recent formulation CHF5633 containing analogues of both SP-B and SP-C in a mixture of DPPC and PG, recently entered phase II clinical trial (ClinicalTrials.gov) after promising results in animal models [12, 13] and optimistic safety and tolerability tests in humans [14] .
Following its use in replacement therapy, the unique properties of PS are also scrutinized for distinct pharmaceutical applications in inhalation therapy. Due to its notable surface-spreading capabilities, exogenous PS is increasingly considered as a valuable excipient to formulate small molecular drugs, biotherapeutics as well as drugloaded nanocarriers (nanomedicines) to promote their distribution along the entire respiratory epithelial surface [15] . Encapsulating drugs into nanocarriers can promote their delivery across extra-and intracellular barriers imposed by the human body. Nanoparticle (NP)-encapsulated drugs are also actively investigated to improve local and/ or systemic drug deposition following administration via the pulmonary route. The latter holds many advantages as it is non-invasive, permits self-medication and allows to reduce the drug dose as high local drug concentrations can be reached following pulmonary deposition. Despite the benefits that nanocarriers can offer for different classes of drugs, e.g. improving drug solubility of poorly soluble low molecular weight drugs or facilitating intracellular drug delivery of macromolecular drugs such as nucleic acids, the lung tissue also harbors many threats that can downgrade nanomedicine performance [16] . For instance, upon deep lung deposition nanomedicines adsorb PS-related components on their surface, which can strongly influence their biological activity [17, 18] . In particular, the interplay between (endogenous or exogenous) lung surfactant and nanomedicines is subject of intensive investigation, probing its impact on NP distribution, cell targeting and both extra-and intracellular drug delivery [19] . Likewise, dependent on the applied dose and their physicochemical properties (size, surface charge and hydrophobicity), inhaled NPs can negatively influence the function of endogenous PS, possibly leading to toxic effects [20] [21] [22] [23] . Hidalgo and colleagues comprehensively summarized the potential detrimental effects that NPs might have on PS functionality, either directly or indirectly. The latter refers to NP-mediated induction of pulmonary inflammation and/or oxidative stress, which might indirectly damage PS components. Direct inactivation is typically the result of the formation of a surfactant corona around the NP, thereby sequestering essential PS components, in particular structural proteins as SP-B and SP-C. In addition, accumulation of the NPs in the fluid domains of the surfactant film can alter the lateral diffusion of phospholipids and disturb surfactant dynamics [23] . The role of SPs, especially SP-B, on surfactant inactivation will be further described in Section 3.
Although PS is generally regarded as an important extracellular barrier for drug delivery, including nanomedicine-based therapeutic [24] . strategies, recent research strongly suggests that this biomaterial could also be exploited to improve drug transport. Although they constitute a relatively minor fraction of PS, the presence of all four surfactant proteins in PS is key for its biological and biophysical properties. These specific properties are not only related to their endogenous function in breathing and host defense, but could also be exploited to support (pulmonary) drug delivery. In this short review, we will first discuss the use of (clinical) pulmonary surfactant as a drug carrier to promote drug spreading and transport along the alveolar interface. Next, each lung surfactant protein will be introduced from a biochemical structural and functional point of view, aiming to connect these characteristics to their value in biomedical applications.
Pulmonary surfactant and drug delivery
The alveoli are lined by a thin layer of epithelial cells (0.1-0.4 μm), are well vascularized and overall constitute a large surface area (~100 m 2 ). These properties explain extensive absorption of small molecular drugs with sufficient permeability across the air-blood barrier following pulmonary administration. Almost two decades ago, it was demonstrated that formulation with PS could enhance the local effect of the intratracheally administered aminoglycoside antibiotic tobramycin to rats infected with the gram-negative Klebsiella pneumoniae [25] . Moreover, the latter was able to reduce systemic exposure of the drug. In analogy with liposomes, i.e. nanosized vesicles composed of a phospholipid bilayer enclosing an aqueous core, the incorporation of different drug classes into proteolipid vesicles made of PS components has been approached as a promising strategy since years [26, 27] . Following the concept of using liposomes as a way to encapsulate and improve bioavailability of hydrophobic compounds, surfactant liposomes have been proposed to facilitate delivery of poorly water-soluble drugs into lung airspaces. However, the relative efficacy of such surfactant lipid/drug combinations has been poorly evaluated. Recent studies have demonstrated that the intrinsic ability of PS lipid-protein complexes to adsorb and spread along air-liquid interfaces can certainly be used to facilitate local interface-assisted drug delivery [28] . For a lung surfactant preparation to work properly, the adsorption of surfaceactive material onto the air-liquid interface must occur very rapidly [29] . As mentioned above, this interfacial adsorption activity is critically dependent on the action of the two hydrophobic surfactant proteins SP-B and SP-C. These proteins also facilitate a rapid macroscopic spreading of lipid-protein complexes across longer distances using the air-liquid interface as a shuttle. In the absence of surfactant proteins, liposomes adsorb very slowly to the interface and do not spread efficiently. In the study by Hidalgo et al., it was demonstrated that hydrophobic drugs such as corticosteroids can be incorporated into PS vesicles, being transferred into and spread along the interface [28] . Interface-assisted drug spreading can thus be regarded as a relatively new concept toward improved pulmonary drug delivery, provided that an appropriate surfactant preparation is applied to formulate the drug. Here, the hydrophobic SP-B and SP-C, or synthetic surrogates that closely mimic their interfacial activity, could play a central role (Fig. 2) .
Interestingly, extrapolation of the concept of lung surfactant-assisted delivery to more hydrophilic drugs is in part hampered by the high permeability and instability of PS membranes. It has been shown that the insertion of SP-B and SP-C into phospholipid membranes increases their permeability to small polar molecules such as calcein, fluorescent probes like FM1-43 [30] or even large hydrophilic polymers of up to a few nanometers of hydrodynamic radius (Perez-Gil and coworkers, Raemdonck and coworkers, unpublished). Hence, PS might also be less suited to improve spreading of hydrophilic macromolecular drugs following inhalation therapy. Nevertheless, next to small molecules this concept of PS-supported drug delivery has also been evaluated for hydrophilic biotherapeutics such as antimicrobial peptides, antibodies, antioxidant enzymes and even viral particles [31] [32] [33] [34] . A future subject of investigation is the PS-supported spreading of nanomedicines, likely further extending this concept to other classes of (hydrophilic) drugs that are amenable to nanocarrier encapsulation [35] . Of note, when considering treatment of pulmonary pathologies (e.g. lung infections, idiopathic pulmonary fibrosis, COPD) with an intrinsic surfactant impairment, the application of PS as a drug delivery vehicle could serve a dual purpose, i.e. to assist in interfacial drug spreading as well as restoration of endogenous surfactant function.
Adding to the complexity, Hidalgo et al. hypothesized the involvement of the processes that regulate surfactant homeostasis and recycling to drug delivery and drug spreading [23] . During successive surfactant compression-expansion cycling, distinct surfactant components are released from the stable surfactant film and subsequently internalized by type II pneumocytes and alveolar macrophages (AM) for further processing or cleared from the lung via the mucociliary escalator. This surfactant recycling also involves the hydrophilic collectins. These fragments of 'used' surfactant are continuously renewed with freshly secreted surfactant material. It is conceivable that drugs or NPs that are inserted in the surfactant film can hitchhike on this pool of depleted surfactant to further distribute throughout the lung or to promote internalization by the abovementioned cell types.
Hydrophilic surfactant proteins

Surfactant protein A
Pulmonary surfactant protein A (SP-A) is produced by alveolar epithelial type II cells and Clara cells in the alveolar region. SP-A is the most abundant protein in lung surfactant, where it takes about 5-6% by mass. It belongs to the collectin protein family, i.e. Ca 2+ -dependent lectins that contain collagen-like domains in their structure [36] . Each SP-A monomer contains four domains in its sequence including a) an Nterminal segment rich in cysteines involved in covalent oligomerization, b) a collagen region composed of a number of (Gly-X-Pro) repeats, c) a connector segment adopting a coiled-coil alpha-helical conformation, and d) a globular glycosylated carbohydrate recognition domain (CRD). Monomers trimerize through the collagen domain and the coiled coil helical connector, while six trimers assemble into the octadecameric macromolecular complex that is found as the native protein form in the lung airspaces. The CRD lectin domains of SP-A bind sugar residues at the surface of multiple microorganisms, including bacteria, viruses and fungi in a Ca 2+ -dependent manner, marking them for clearance by AM [37, 38] . These opsonization properties are dependent on the multimeric character of the protein, as the binding affinity of SP-A to surfaces exposing multiple ligands exhibits a high cooperativity. AM express receptors that recognize the collagen-like domain of SP-A, triggering phagocytosis and clearance of SP-A-decorated bodies [39] . Interestingly, SP-A is also able to bind to phospholipid membranes, with a particular affinity for DPPC-rich domains [40] . Association of SP-A to the large membrane network that surfactant forms at the alveolar epithelium could optimize the distribution of the protein to protect the large respiratory surface from the entrance of potential pathogens. Although mainly governed by the small hydrophobic SPs, binding of SP-A to surfactant lipids also promotes the adsorption and spreading of surfactant along the air-liquid interface [41] . The ability of SP-A to bind sugars, phospholipids and hydrophobic surfaces makes it also prone to bind other entities such as exogenously delivered drug-loaded NPs, which are subsequently marked for phagocytosis and clearance by AM [42] [43] [44] .
Role of SP-A in drug delivery applications
Once secreted and having exerted its function, SP-A is involved in the surfactant recycling by type II cells and AM. The interplay between SP-A and type II cells includes a wide range of effects, from the regulation of surfactant lipid turnover to modulation of cytokine secretion [45] . When SP-A is present, type II cells incorporate a higher amount of lipids via clathrin-mediated endocytosis, dependent on the presence of the protein P63. This type II-cell surface protein binds both free SP-A or SP-A/lipid complexes that are subsequently internalized. Once endocytosed, P63 follows the recycling pathway leading to its transport back to the cell surface in a controlled manner. When levels of SP-A in the alveolar space are low, P63 will remain in the endoplasmatic reticulum causing reduction of lipid uptake. Thus, high levels of SP-A determine a higher expression of P63, contributing to surfactant homeostasis [46, 47] . The latter is also regulated by the binding of SP-A to the cell surface of AM via its CRD domain. SP-A inhibits and stimulates at the same time inflammatory responses of AM reducing the LPS-induced TNF-α production or inducing an opsonin-like mechanism involved in phagocytosis of pathogens and inhaled NPs [45, 48] .
This opsonization model was assessed by Ruge et al. using magnetite nanoparticles (mNPs) coated with different materials to modulate their surface properties. Here, SP-A binding induced the formation of mNP aggregates, thereby promoting subsequent scavenging by phagocytic cells. Interestingly, SP-A preferably interacts with lipophilic coated mNPs, in agreement with its natural association with phospholipids in the alveolar space [42] , a treat that could be exploited to redirect nanomedicines to specific cell types following pulmonary administration. Although AM are generally regarded as a barrier for nanomedicinemediated drug delivery in the lung, this cell type constitutes an important target for pulmonary pathologies with an important inflammatory component, including asthma, COPD or infectious diseases such as tuberculosis [49] [50] [51] . Specifically, Mycobacterium tuberculosis (MTB) finds its niche inside AM phagosomes, exploiting mannose, complement and scavenger receptors for cell entry and using host lipids as carbon source during replication and infection [52, 53] . Interestingly, while SP-D inhibits intracellular entry and growth of MTB [54] , SP-A is able to promote MTB uptake by and infection of AM in multiple ways.
To protect the alveolar region from an uncontrolled inflammatory response, SP-A reduces Toll-like receptor (TLR) signaling involved in proinflammatory cascades [55] . Simultaneously, SP-A promotes lipid uptake (vide supra) [56] and hampers the production of reactive-nitrogen intermediates [57] , thereby dramatically enhancing mycobacterium survival. Additionally, SP-A stimulates the trafficking of mannose receptors (MR) to the AM cell surface, as demonstrated by Beharka and colleagues, supporting AM infection by MTB [58] . The possibility to use nanomedicines to increase intracellular drug concentration within AM has already been explored with different types of NPs [51, 59] . Considering the impact of SP-A in MTB infection, Ruge and colleagues explored its role as uptake enhancer for lung delivery of PLGA/PLA nanoparticles (PLGA/PLA-NPs) decorated with mannose residues to interact specifically with the CRD region of lipid-free SP-A in the alveoli. Interestingly, mannose decoration already increased the uptake of PLGA/PLA-NPs, which was however further enhanced in presence of SP-A. These results pointed towards a double mechanism of action of SP-A involved in the enhanced intracellular uptake, occurring indirectly via mannose receptors (up-regulated by SP-A) and directly via SP-A receptors through the formation of SP-A-decorated PLGA/PLA-NPs via mannose moieties on the NP surface [60] . Next to exploiting SP-A as a ligand for receptor-mediated targeting to resident AM or type II pneumocytes, SP-A was also investigated as an abundant lung-specific receptor with the aim to improve pulmonary drug retention. Following initial studies on the design of liposomes decorated with a SP-A polyclonal antibody [61] , Li et al. reported on the application of these SP-A targeted liposomes for methylprednisolone (MPS) delivery in the lung [62] . Using a lung injury rat model, SP-A nanobody-conjugated liposomes demonstrated significantly higher levels and an increased residence time of MPS, leading to decreased levels of TNF-α, IL-8, and TGF-β1 in bronchoalveolar lavage fluid and NF-κB in the lung tissue.
Surfactant protein D
Next to SP-A, surfactant protein D (SP-D) is the other collectin that can be found in surfactant, although not exclusive to the lung tissue. It participates in innate defense mechanisms in lung and gut mucosa, where it opsonizes potential pathogens in a Ca 2+ -dependent manner, promoting their agglutination and subsequent clearance [63, 64] . Similar to SP-A, SP-D molecules organize in trimers through the formation of triple-helix collagenic segments and the coiled-coil-like association of helical bundles that connect the collagenic stems with globular trimeric carbohydrate recognition domains (CRDs). Two SP-D trimers assemble into hexamers and two hexamers into X-shaped dodecamers, the most frequent SP-D oligomer found in the airways [65] . Hexamers and dodecamers also associate into more complex "fuzzyball"-like large oligomers, with a high ability to agglutinate multiple microorganisms that are subsequently cleared through the mucociliary escalator of the upper airways. Surprisingly, apart from its innate defense-related activities, SP-D has been reported to participate in regulating surfactant homeostasis as well. Lack of SP-D was associated with an exacerbated accumulation of surfactant in the airways, which was not properly cleared [66] . However, the exact mechanisms connecting SP-D and surfactant recycling to macrophages (involved in surfactant lipid catabolism), are still unknown.
Role of SP-D in drug delivery applications
Although SP-D is not found in association with membranes and preferentially associates with hydrophilic structures, the neck region of SP-D seems to be involved in phospholipid interaction [67] . Based on this, Nogueira and colleagues developed a SP-D inspired peptide, mimicking the neck domain of the native protein, as targeting anchor for drug delivery. Working on a liposomal formulation of DOPE/Chol/ DSPE-mPEG, different SP-D derived peptides were evaluated for their capability to insert in the liposome bilayer and allow liposomal functionalization with folic acid. Improved cellular delivery of both hydrophobic anti-inflammatory drugs (celecoxib and CORM) and the hydrophilic chemotherapeutic/anti-arthritis methotrexate (MTX) was observed for folate-decorated liposomes via the selected SP-DS3 anchor in cell types overexpressing the folate receptor (FRα). Interestingly, the SP-DS3-folate construct demonstrated a faster delivery compared with the frequently used DSPE-PEG folate lipid, likely due to its smaller dimensions [68] . MTX-containing liposomes with the SP-DS3 anchor (0.75 molar ratio) were tested in vivo in arthritic mice targeting FRβ expressing macrophages, i.e. activated target cells in rheumatoid arthritis, showing complete prophylactic efficacy with no signs of inflammation in arthritic mice model treated before disease onset [69] . A very recent report from the same group showed the application of the SP-D peptide to functionalized liposomes with Fab antibody fragments to enable receptor-mediated drug delivery of liposomal cargo [70] .
Different studies reported the effects of the two pulmonary collectins SP-A and SP-D in phagocytosis of viruses, bacteria, allergens and apoptotic cells, regulating phagocytes inflammatory responses (Fig. 3) [57]. Erpenbeck and colleagues investigated the mechanism behind the increased phagocytosis of pollen-allergen starch granules promoted by recombinant fragments of SP-D and SP-A of different origin [71] . The formation of the dodecameric structure appeared essential for the interaction and determined increased phagocytosis without necessarily promoting aggregation of the allergen particles. Further studies from Kendall et al. highlighted the role of the positively charged residues present in the CRD region as the critical component involved in the enhanced uptake of NPs in the presence of native human or recombinant human SP-D, independent from the lectin activity as such [72] . As it occurs with SP-A, binding of SP-D has been shown to define the fate of inhaled NPs, depending on their material composition and coating. SP-A showed a preferred interaction with lipophilic NPs while SP-D was shown to be more incline with interaction with hydrophilic surfaces [17, 42, 43] . Interaction with lung surfactant collectins can therefore be an important factor to take into account when designing novel strategies for pulmonary drug delivery.
Antiviral activity of SP-A and SP-D
The first report on the antiviral activity of SP-A describes the promoted phagocytosis of fluorescein isothiocyanate-labeled herpes simplex virus by addition of SP-A to the culture medium of rat [73] . The antiviral effect of SP-A was shown in the treatment of Porcine reproductive and respiratory syndrome virus infection, a relevant infectious disease in the swine industry. Recombinant porcine SP-A exerts an antiviral activity as result of a double mechanism of action, preventing the infection of both cell-free virus particles and transmission between infected and uninfected cells. Interestingly, Li and coworkers showed an interaction between SP-A and virus glycoproteins, responsible for blocking cell-to-cell transmission [74] . Similar antiviral activity in vitro was reported also against the influenza A virus, via binding of the glycoprotein hemagglutinin thus preventing cellular infection [75] . The ability of SP-D to promote clearance of viruses has been shown for Influenza A virus, respiratory syncytial virus and vaccinia virus [76] . 
Hydrophobic surfactant proteins
Surfactant protein B
The lack of pulmonary surfactant protein B (SP-B) is incompatible with life. Mutations in the SP-B gene SFTPB at birth are the cause of fatal respiratory failure [78, 79] , as the presence of SP-B in lung surfactant is strictly required for transfer of surfactant lipid species into the air-liquid interface to form stable surface-active films, in particular at the end of expiration [80] .
SP-B belongs to the saposin-like protein family (SAPLIP), a highly homologous group of membrane-interacting proteins possessing a common saposin fold, with dominating alpha-helical conformation able to interact with lipids, six cysteines in conserved positions responsible for the formation of three intramolecular disulfide bridges and conserved hydrophobic amino acids content [81] . The protein contains 4-5 cationic amphipathic helical segments, which are thought to interact with the headgroup region of phospholipid membranes, with a parallel orientation with respect to the bilayer surface. Most saposins have an alternative soluble conformation, in which the amphipathic helices pack in two halves, with the hydrophobic faces protected against each other to avoid exposure to aqueous environments. The two alternative configurations allow to most protein members of this family to be either involved in lipid transport and/or metabolism, with some degree of membrane perturbing activity, modulating the packing and permeability of phospholipid membranes. Interestingly, SP-B is the only saposin protein that is permanently associated with biological membranes. In vitro, it has been widely demonstrated that SP-B promotes membrane-membrane contact that depends on the establishment of protein-protein interactions. SP-B-promoted membrane aggregation ends in true membrane fusion as a consequence of a deep perturbation of membrane packing at the sites of membrane-membrane contacts. As a result, SP-B is able to convert a dispersion of unilamellar vesicles into large multilamellar membrane assemblies [30, 82] . Current models propose that SP-B is crucial to trigger cooperative transfer of surfactant phospholipids from lamellar bodies, i.e. the organelles in ATII cells where surfactant is stored and from which it is secreted, into the alveolar interface [83] and to form highly cohesive multilayered surfactant films at the air-exposed respiratory surface [84] . Recent studies have revealed that SP-B could form large supramolecular assemblies in the form of ring-shaped hydrophobic channels that connect opposing membranes and facilitate distal transport of phospholipids [85] . Such SP-B-based hydrophobic channels could also provide the structural basis for other activities related with facilitating the entrance of membrane-impermeable molecules into cells [30] . As a matter of fact, it has been recently revealed that SP-B is able to act at the plasma membrane of pneumocytes, activating receptors and channels that could modulate surfactant secretion to establish highly conductive membrane networks at the alveolar airspaces [86] .
The presence of SP-B in surfactant plays an essential role in its susceptibility towards inactivation. As previously reported, PS function can be significantly hampered by NP formulations in a dose-dependent manner [23] . Beck-Broichsitter and colleagues investigated whether the protein fraction of the surfactant could govern the extent of inactivation of surface active SP-B/recombinant SP-C (rSP-C) proteolipid mixtures following their exposure to polymeric NPs. Interestingly, the presence of SP-B was critical, as it made proteolipid mixtures more resistant to NPs inactivation, compared to rSP-C based surfactant [87] . Especially, the segregation of SP-B in the NP surfactant corona would therefore be a key step for surfactant inactivation, also in part explaining the impact of NP surface charge on the latter. Indeed, as both SP-B and SP-C bear cationic charges, they will be bound to a greater extent by anionic NPs, increasing the risk on surfactant impairment [23] .
Membrane perturbation effect of SP-B in antibacterial therapies and nucleic acid delivery
Different antimicrobial peptides like NK-lysin, amoebapore and granulysin belong to the SAPLIP family and their amino acids composition defines the interaction with bacterial membranes, leading to permeabilization, fusion and aggregation. Based on the similarity between SP-B and previously mentioned peptides, Ryan et al. investigated the interaction of native SP-B and its derived synthetic peptides with Gram-positive and Gram-negative bacteria in vitro and potential antimicrobial activity. Low concentrations of the SP-B and derived synthetic peptides showed a strong antimicrobial activity in vitro for K. pneumoniae, S. aureus, group B streptococcus, and P. aeruginosa, suggesting them as alternative coadjuvant therapies for bacterial pneumonia [88] . SP-B is processed from a proprotein (proSP-B) of which the N-terminal propeptide (SP-B N ) in part regulates the intracellular trafficking of the mature SP-B. Interestingly, the non-cationic SP-B N also contains a SAPLIP domain by which it has demonstrated antibacterial activity in the acidic lysosomes of infected AM [89] . The membrane perturbation effect promoted by SP-B depends on both electrostatic and hydrophobic interactions, mediated by the positive residues of N-and C-helices and aromatic amino acids involved in membrane insertion, respectively [81] . Interestingly, these specific features are common to amphipathic cell penetrating peptides (CPPs), widely used in drug delivery for their ability to transport cargo across cellular membranes [90] . Although their factual mechanism of action to promote intracellular drug delivery remains subject to debate, recent studies suggest the involvement of both passive and active delivery routes. Energy-independent mechanisms include transient pore formation and membrane translocation, while active processes involve macropinocytosis as well as clathrin-mediated or caveolar endocytosis, defined by the type and concentration of the peptide [91] . In latter case, the CPPs should additionally display endosomal escape activity to allow access of therapeutic cargo to the cytoplasm of the cell. In 1994, Baatz and colleagues were the first to report the use of a 10 kDa poly(lysine) conjugate of SP-B to deliver DNA into airway cells in vitro. In this study, SP-B was selected for its ability to promote cellular uptake in lung epithelial cells via fusion with the plasma membrane and for its nontoxic and non-immunogenic nature [92] . Almost ten years later, Karagiannis et al. covalently conjugated a library of cationic CPPs to the surface of lipidoid-based NPs with the aim to identify novel peptides that can promote intracellular siRNA delivery. Interestingly, a~2 kDa cationic peptide, derived from native SP-B, significantly improved siRNA delivery in vitro and in vivo, reducing the hepatic expression of Factor VII following intravenous injection of the peptide-decorated NPs [93] . In the same study, different endocytosis inhibitors were used to identify the cellular uptake pathway provoked by the peptides, reinforcing the macropinocytosis hypothesis for arginine-rich CPPs [94, 95] . Related to this, Qiu and colleagues reported on the cationic amphiphilic peptide KL4, a synthetic peptide mimicking some sequence patterns of the C-terminal domain of SP-B and also in clinical trials as surfactant replacement therapy, as siRNA carrier for lung delivery [96] . The KL4 peptide was able to form nanosized complexes with siRNA and allowed functional siRNA delivery in lung epithelial cells in vitro with reasonable efficiency.
In the context of pulmonary delivery of NPs, De Backer et al. reported on a bio-inspired nanocomposite, composed of a siRNA-loaded polymeric matrix core surrounded by a shell of clinical PS [97] . Unexpectedly, it was observed that the PS outer layer on the NPs markedly enhanced intracellular siRNA delivery in lung epithelial cells and (primary) AM, for which also in vivo proof-of-concept was obtained [15, 98] . Very recently, Merckx et al. identified SP-B as the key component involved in the enhanced siRNA delivery observed for the abovementioned proteolipid-coated nanocomposites, for the first time linking native and unconjugated SP-B to improved cellular delivery of small RNA therapeutics. The delivery enhancing effect of SP-B was likewise demonstrated in vivo, using a murine LPS-induced acute lung injury (ALI) model [99] . Of note, the effect of SP-B on siRNA delivery was observed with as little as 0.2 wt% of the protein relative to the total of mass of lipids used in the nanocomposite (Fig. 4) , indicating a potent mode-of-action, albeit the exact mechanism behind the enhanced silencing promoted by the PS remains elusive to date. Of note, next to repurposing SP-B to promote cellular delivery of nucleic acid therapeutics, SP-B deficiency is also regarded as a valid target for gene therapy. In this regard, Mahini et al. convincingly demonstrated the value of in vivo genome editing in a validated mouse model of SP-B deficiency [100] . Earlier work of Kormann et al. described the successful aerosolization of modified SP-B-encoding mRNA to restore its expression in SP-B deficient mice [101] .
Surfactant protein C
The pulmonary surfactant protein C (SP-C) has been described as the most hydrophobic protein in the human proteome. Its presence in the lungs as a result of the expression of the SFTPC gene was initially identified as a marker of differentiation of the pulmonary tissue, and is currently used as indicator of type II pneumocytes. However, the physiological role of SP-C is still far from understood. In contrast to SP-B, its absence in animal knockout models does not impair breathing function at first instance [102] . Still, and depending on genetic background, prolonged absence of functional SP-C seems to be associated with severe chronic respiratory problems [103] , indicating that SP-C may be required for the full mechanical stabilization of the delicate alveolar structure of mammalian lungs along numerous respiratory cycles.
The structure of SP-C, a lipopeptide of only 35 amino acids, was determined in the highly apolar organic solvents in which it is soluble, such as chloroform. It adopts an extremely regular and stable alphahelical conformation comprising residues 10-35, perfectly suited to adopt a transmembrane orientation in DPPC-rich phospholipid membranes, as found in the alveolar surfactant [104] . The N-terminal segment contains invariable proline, cysteine and cationic residues, responsible for the defined configuration at the headgroup region of membranes and interfacial films. Peptides synthetized with the sequence of the N-terminal segment of SP-C adopt an amphipathic betahairpin structure with intrinsic ability to interact and perturb phospholipid membranes [105, 106] . The cysteines in SP-C, two in most animal species, are always palmitoylated, strongly contributing to the hydrophobicity of the protein. It has been proposed that palmitoylation might be required to promote monolayer-bilayer structural transitions [107] and to maintain association of the protein with the extremely packed surfactant films at exhalation [108] .
Recent work has revealed that SP-C might be involved in promoting a highly dynamic metabolism of surfactant structures at the alveolar spaces. The protein is able by itself to fragment large phospholipid membranes into very small (around 25 nm diameter) nanovesicles [82] . Considering that SP-C seems to prefer partitioning into membrane regions that are enriched in unsaturated phospholipids and cholesterol [108, 109] , membrane fragmentation could be part of a surfactant recycling mechanism by which SP-C contributes to route the less surfaceactive species in surfactant towards macrophages. In addition, it has been proposed that SP-C facilitates clearance of certain pro-inflammatory molecules such as endotoxin (lipopolysaccharide, LPS) by macrophages through non-inflammatory pathways [110] [111] . Our current view is that SP-C might be involved in a dynamic modulation of surfactant structure and composition, making surfactant more adaptable to different physiopathological situations. The lack of SP-C might introduce a factor of stress and inadaptability that might be particularly triggered in pathological situations such as inflammation, infection or lung injury. The recent finding that both SP-C and SP-B are detected in common supramolecular protein complexes in surfactant, and that homo-and hetero-oligomerization is mutually influenced [112] , portray a complex picture that still requires further investigation.
SP-C in targeted lung delivery
The expression of SP-C on the apical membrane of alveolar type II cells is directly correlated to the health condition of the lungs, making this protein essential for the homeostasis and the protection of the pulmonary epithelium. Although the absence of SP-C does not result in direct impaired surfactant metabolism or breathing function, recent work revealed that compromised SP-C expression results in type II cells apoptosis, due to an increase in p53 expression [113] . In contrast with the other SPs, SP-C is produced and expressed only by the alveolar epithelial cells and this specific distribution made it an interesting target for the development of type II cell-specific drug delivery strategies. Alveolar epithelial cells are essential in surfactant metabolism but are also involved in a wide range of pathologies, including lung cancer and inflammatory lung disease. Wu and colleagues explored the conjugation of an anti-SP-C antibody to lipoplexes (LP ANTI-SP-C ) for a dual purpose, i.e. targeted microRNA delivery to alveolar type II cells as well as increasing drug retention time in vivo [114] . The simultaneous presence of SP-C on the surface of type II cells and extracellularly in the surfactant films makes the anti-SP-C antibody able to interact at both levels. It was anticipated that the anti-SP-C antibody would stimulate the specific uptake by alveolar type II epithelial cells interacting both with SP-C expressed on the luminal membrane as well as with the SP-C secreted with surfactant phospholipids, allowing the LP ANTI-SP-C to follow the surfactant recycling pathway, as mentioned above. The intranasally-administered LP ANTI-SP-C loaded with nucleic acids showed high specificity in vivo for type II cells, with retention times up to 48 h in target tissues and minimal levels in liver, kidneys or spleen. As indicated above, SP-B and SP-C share the ability to perturb membrane structures. Interestingly, and in contrast to its cationic and hydrophobic counterpart SP-B as reported by Merckx et al., no improved intracellular delivery of siRNA could be noted for SP-C when reconstituted in lipidpolymer core-shell nanocomposites [99] .
Although not belonging to the collectin family, SP-C does participate in the innate immunity as demonstrated from its binding to LPS. The interplay between SP-C and LPS is dose-dependent and the surfactant protein promotes the adaption of CD14 involved in the association with pathogen-associated patterns as LPS [110] . CD14 is expressed on the membrane of macrophages and recognizes LPS leading to the internalization of the LPS-LPS binding protein (LBP) complex. SP-C determines a change in the CD14 conformation, which results in increased binding to LPS. A similar mechanism was shown for SP-A, suggesting an important influence of the two surfactant proteins in CD14 activation [115] . Beside this interaction, Mizuno et al. investigated the adjuvant effect of Surfacten®, a bovine pulmonary surfactant preparation, when co-administered with influenza virus hemagglutinin (HA) vaccine. Here, SP-C specifically stimulated expression of MHC II, CD40 and CD86 of CD11c + cells isolated from the nasal cavity after treatment with Surfacten/surfactant lipids containing SP-C and HA vaccine, inducing both systemic IgG and mucosal anti-viral secretory IgA (S-IgA) responses and suggesting the use of SP-C supplemented lipids as alternative mucosal adjuvant formulation [116] .
Conclusions
As synthetic drug carriers often fail to combine biocompatibility with efficient drug delivery, in the last decades the implementation of endogenous components to formulate drug substances has gained interest. In contrast to general belief, pulmonary surfactant should not simply be regarded as a barrier for pulmonary drug delivery. Following elaborate experience in the application of pulmonary surfactant as surfactant replacement therapy for the treatment of respiratory distress syndrome, evidence is now mounting that this biomaterial can even promote drug delivery. The peculiar biochemical profile of PS-associated surfactant proteins (SPs) has encouraged a more elaborate study of their specific interactions with extra-and intracellular membranes, proteins or particles. Despite constituting less than 10% of the total surfactant mass, SPs have demonstrated substantial impact on various key steps in the drug delivery process, including the modulation of pulmonary distribution of drugs and drug carriers (e.g. nanomedicines), promoting cellular uptake and targeting of nanomedicines as well as enhancing intracellular delivery of membrane-impermeable therapeutics. Interestingly, the endogenous biophysical mode-of-action, e.g. the involvement in surfactant recycling and immune surveillance of the collectins SP-A/SP-D and the membrane-perturbing effect of the hydrophobic surfactant proteins SP-B/SP-C, can perfectly explain their beneficial effect on pulmonary drug delivery. As highlighted in this review, the development of NPs or treatment strategies making use of SPs or derivatives represent the perfect example of adapting a specific instrument from nature's toolbox to different pathological settings, gaining biological insights to shape them into therapeutic solutions. Although SPs are mainly found in the lung, it is conceivable that these proteins could also be repurposed to assist in drug delivery strategies to other tissues and organs exploiting other administration routes.
